This is the part of the strategy that is not clear for me - how the EuGenie reader becomes the platform for rapid diagnosis, vs supplying / licencing anteobind or their own test strips. We've heard many times the capacity for supplying tests but off the top of my head not a lot of discussion about how to chase down sales of readers and get their tech embedded in the right organisations.
This is the part of the strategy that is not clear for me - how...
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.22M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.9¢ | 2.7¢ | $17.68K | 634.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 541015 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 4693635 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| ADO (ASX) Chart |